載入...
Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 30...
Na minha lista:
| 發表在: | Breast J |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7496313/ https://ncbi.nlm.nih.gov/pubmed/31782589 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/tbj.13686 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|